归创通桥-B(02190)公布2024年业绩经调整溢利约1.24亿元同比增长16.63倍

智通财经

Mar 20, 2025

智通财经APP讯，归创通桥-B(02190)公布2024年业绩，收入约7.82亿元，同比增长48.3%;毛利约5.6亿元，同比增长45.4%;经调整溢利约1.24亿元，同比增长16.63倍;年内溢利约1亿元，同比扭亏为盈;每股基本盈利0.3101元。

于2024年，国际业务再创佳绩，实现收入人民币2260万元，与2023年同期相比增长58.2%，主要来自欧洲和亚洲地区。

于2024年，神经血管介入产品的销售收入较2023年增加38.4%，主要是由于银蛇颅内支持导管、凤颅内动脉瘤栓塞弹簧圈、通桥麒麟血流导向装置、蛟龙取栓支架(蛟龙CRD)及北斗SS神经血管导丝等主要产品的收入持续增长;及公司持续致力于提高产品在各级医院的渗透率。

于2024年，外周血管介入产品的销售收入较2023年增加74.5%，塬因是公司不断努力扩大市场准入、提高医院渗透率及扩大分销网络，使得UltraFree 药物洗脱PTA球囊扩张导管(UltraFree DCB)、ZYLOX Octoplus可回收腔静脉滤器、腔静脉滤器抓捕器及ZYLOX Swan静脉腔内射频闭合导管的销售收入快速增长;及公司的外周疾病治疗产品组合持续商业化上市，包括ZYLOX Phoenix外周可解脱带纤维毛弹簧圈栓塞系统及ZYLOX Penguin静至髂静脉支架系统，该等产品于2024年年初左右获得批准。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2520558424"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520558424\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2520558424?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-03-20 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520558424","market":"hk","top_or_hot":-1,"title":"归创通桥-B(02190)公布2024年业绩 经调整溢利约1.24亿元 同比增长16.63倍","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02190\">归创通桥-B</a>(02190)公布2024年业绩，收入约7.82亿元，同比增长48.3%;毛利约5.6亿元，同比增长45.4%;经调整溢利约1.24亿元，同比增长16.63倍;年内溢利约1亿元，同比扭亏为盈;每股基本盈利0.3101元。</p><p>于2024年，国际业务再创佳绩，实现收入人民币2260万元，与2023年同期相比增长58.2%，主要来自欧洲和亚洲地区。</p><p>于2024年，神经血管介入产品的销售收入较2023年增加38.4%，主要是由于银蛇颅内支持导管、凤颅内动脉瘤栓塞弹簧圈、通桥麒麟血流导向装置、蛟龙取栓支架(蛟龙CRD)及北斗SS神经血管导丝等主要产品的收入持续增长;及公司持续致力于提高产品在各级医院的渗透率。</p><p>于2024年，外周血管介入产品的销售收入较2023年增加74.5%，塬因是公司不断努力扩大市场准入、提高医院渗透率及扩大分销网络，使得UltraFree 药物洗脱PTA球囊扩张导管(UltraFree DCB)、ZYLOX Octoplus可回收腔静脉滤器、腔静脉滤器抓捕器及ZYLOX Swan静脉腔内射频闭合导管的销售收入快速增长;及公司的外周疾病治疗产品组合持续商业化上市，包括ZYLOX Phoenix外周可解脱带纤维毛弹簧圈栓塞系统及ZYLOX Penguin静至髂静脉支架系统，该等产品于2024年年初左右获得批准。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>归创通桥-B(02190)公布2024年业绩 经调整溢利约1.24亿元 同比增长16.63倍</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n归创通桥-B(02190)公布2024年业绩 经调整溢利约1.24亿元 同比增长16.63倍\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-20 20:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1264956.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，归创通桥-B(02190)公布2024年业绩，收入约7.82亿元，同比增长48.3%;毛利约5.6亿元，同比增长45.4%;经调整溢利约1.24亿元，同比增长16.63倍;年内溢利约1亿元，同比扭亏为盈;每股基本盈利0.3101元。于2024年，国际业务再创佳绩，实现收入人民币2260万元，与2023年同期相比增长58.2%，主要来自欧洲和亚洲地区。于2024年，神经血管介入产品...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1264956.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02190","symbol_name":"归创通桥","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1264956.html","article_id":"2520558424","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520558424","pubTimestamp":1742472373,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，归创通桥-B 公布2024年业绩，收入约7.82亿元，同比增长48.3%;毛利约5.6亿元，同比增长45.4%;经调整溢利约1.24亿元，同比增长16.63倍;年内溢利约1亿元，同比扭亏为盈;每股基本盈利0.3101元。于2024年，国际业务再创佳绩，实现收入人民币2260万元，与2023年同期相比增长58.2%，主要来自欧洲和亚洲地区。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02190":"归创通桥","BK1587":"次新股","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1100":"医疗保健设备"},"translate_title":"Guichuang Tongqiao-B (02190) announced its 2024 results with an adjusted profit of approximately 124 million yuan, a year-on-year increase of 16.63 times","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02190":1},"content_text":"智通财经APP讯，归创通桥-B(02190)公布2024年业绩，收入约7.82亿元，同比增长48.3%;毛利约5.6亿元，同比增长45.4%;经调整溢利约1.24亿元，同比增长16.63倍;年内溢利约1亿元，同比扭亏为盈;每股基本盈利0.3101元。于2024年，国际业务再创佳绩，实现收入人民币2260万元，与2023年同期相比增长58.2%，主要来自欧洲和亚洲地区。于2024年，神经血管介入产品的销售收入较2023年增加38.4%，主要是由于银蛇颅内支持导管、凤颅内动脉瘤栓塞弹簧圈、通桥麒麟血流导向装置、蛟龙取栓支架(蛟龙CRD)及北斗SS神经血管导丝等主要产品的收入持续增长;及公司持续致力于提高产品在各级医院的渗透率。于2024年，外周血管介入产品的销售收入较2023年增加74.5%，塬因是公司不断努力扩大市场准入、提高医院渗透率及扩大分销网络，使得UltraFree 药物洗脱PTA球囊扩张导管(UltraFree DCB)、ZYLOX Octoplus可回收腔静脉滤器、腔静脉滤器抓捕器及ZYLOX Swan静脉腔内射频闭合导管的销售收入快速增长;及公司的外周疾病治疗产品组合持续商业化上市，包括ZYLOX Phoenix外周可解脱带纤维毛弹簧圈栓塞系统及ZYLOX Penguin静至髂静脉支架系统，该等产品于2024年年初左右获得批准。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}